RxDoctor Payments Data

Tasha Joseph, APRN

Family · Henderson, NVNPI 1467140046

Payments from drug & device makers

$5,270in general payments, 2019–2025

Across 189 payments — averaging $27.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sumitomo Pharma America, Inc.$812
  • Astellas Pharma US Inc$676
  • Johnson & Johnson$546
  • Dendreon Pharmaceuticals LLC$409
  • Telix Pharmaceuticals$390
  • Urogen Pharma, Inc.$358
  • plus $2K from 17 others

What the payments were for

  • Food & beverage$4,80991%
  • Education$4619%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,270 in reported general payments places this provider in the 90th percentile of 1,501 family providers in Nevada.

See all family providers in Nevada

Medicare billing

Part B allowed, 2024
$133,731
Medicare patients
594
Services billed
2,267

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron30$24,498
MyrbetriqMirabegron21$20,159
Solifenacin Succinate272$11,191
Tamsulosin Hcl371$4,523
Estradiol63$3,630
NitrofurantoinNitrofurantoin Macrocrystal98$3,426
Testosterone Cypionate28$1,456
Alfuzosin Hcl ErAlfuzosin Hcl60$1,202
Desmopressin Acetate11$959
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst64$817
Oxybutynin Chloride ErOxybutynin Chloride27$577
Ciprofloxacin Hcl127$528
Finasteride47$503
Fluconazole50$274
Cephalexin12$258

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$812$24,49830 claims
Astellas Pharma US IncMyrbetriq$676$20,15921 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,501 family providers in Nevada.

Other family in Henderson

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →